Manages incidental finding follow-up using ACR White Paper recommendations. Use when tracking incidentalomas, scheduling follow-up imaging, or managing unexpected findings.
Manages incidental finding follow-up using ACR White Paper recommendations.
Incidental findings — abnormalities discovered on imaging performed for an unrelated indication — occur in up to 40% of CT scans. The ACR Incidental Findings Committee has published organ-specific white papers providing evidence-based management algorithms for adrenal, renal, hepatic, pancreatic, splenic, and thyroid incidentalomas. Without structured tracking, incidental findings are lost to follow-up at alarming rates: studies show 30–70% of incidental findings with recommended follow-up never receive it. Lost follow-up exposes patients to delayed cancer diagnosis and represents a major medicolegal liability for radiologists and referring providers.
The Joint Commission and CMS Conditions of Participation require systems for critical result communication, and many institutions extend this to actionable incidental findings. ACR accreditation standards expect that radiology reports include specific, evidence-based follow-up recommendations for incidentalomas rather than vague "clinical correlation" statements. This skill provides the systematic framework for categorizing, recommending, tracking, and closing the loop on incidental findings.
| Organ | Finding Type | Key Characterization Features | Primary Reference |
|---|---|---|---|
| Adrenal | Nodule | Size, attenuation (HU on non-con CT), washout characteristics | ACR Adrenal White Paper 2017 |
| Kidney | Cystic mass | Bosniak v2019 classification (septations, enhancement, wall features) | ACR Renal White Paper 2017 |
| Kidney | Solid mass | Size, enhancement pattern | ACR Renal White Paper 2017 |
| Liver | Hepatic lesion | Patient population (cirrhosis vs. no), enhancement pattern, size | ACR Liver White Paper 2017 |
| Pancreas | Cystic lesion | Size, duct communication, mural nodularity, main duct dilatation | ACR Pancreas White Paper 2017 |
| Thyroid | Nodule on CT/MRI | Size, suspicious features (calcification, invasion) | ACR Thyroid White Paper 2015 |
| Spleen | Lesion | Homogeneity, enhancement, number | ACR Spleen White Paper 2017 |
| Lung | Nodule (non-screening) | Size, morphology, patient risk factors | Fleischner Society 2017 |
| Size | Attenuation | Recommendation |
|---|---|---|
| ≤1 cm | Any | Benign; no follow-up required |
| 1–4 cm | ≤10 HU on non-contrast CT | Lipid-rich adenoma; no follow-up |
| 1–4 cm | >10 HU | Adrenal CT washout protocol or chemical-shift MRI |
| >4 cm | Any | Surgical consultation (concern for adrenal carcinoma/pheochromocytoma) |
| Any | Suspicious features (heterogeneous, hemorrhage, invasion) | Urgent surgical referral |
Adrenal washout criteria: Absolute washout >60% or relative washout >40% at 15-minute delay = adenoma.
| Bosniak Class | Features | Management |
|---|---|---|
| I | Simple cyst: thin wall, no septa, no enhancement | No follow-up |
| II | Few thin septa, fine calcification, hyperdense (≤3 cm, homogeneous, non-enhancing) | No follow-up |
| IIF | Minimal thickening, many septa, thick calcification | Follow-up: 6, 12, 24 months |
| III | Thickened irregular septa or wall, measurable enhancement | Surgical or active surveillance |
| IV | Enhancing soft-tissue component | Surgical management |
| Size | Features | Recommendation |
|---|---|---|
| <1.5 cm | No worrisome features | No follow-up or MRI in 2 years (varies by institution) |
| 1.5–2.5 cm | No worrisome features | MRI in 1 year, then extend interval |
| >2.5 cm | No worrisome features | MRI/EUS, consider multidisciplinary discussion |
| Any | Mural nodule, main duct >5 mm, solid component | EUS with FNA; surgical consultation |
| Finding | Recommendation |
|---|---|
| ≤1.0 cm, no suspicious features | No further workup in most patients |
| >1.0 cm without suspicious features | Thyroid US recommended |
| >1.5 cm | Thyroid US recommended |
| Any size with suspicious features (calcification, lymphadenopathy, invasion) | Thyroid US + possible FNA |
| Known thyroid cancer history | Thyroid US regardless of size |
Every incidental finding report entry must include:
Incidental [size] [descriptor] [organ] [location].
Per ACR Incidental Findings Committee [organ] White Paper [year]:
Recommendation: [specific modality] in [timeframe].
[Communication documentation if required.]
| Field | Description |
|---|---|
| Patient MRN | Unique patient identifier |
| Finding | Organ, type, size, laterality |
| Detection date | Date of original study |
| ACR category | Classification per white paper |
| Recommended follow-up | Modality + timeframe |
| Due date | Calculated from detection date + recommended interval |
| Ordering provider | Name, NPI, contact |
| Communication date | When provider was notified |
| Follow-up status | Pending, scheduled, completed, lost, patient declined |
| Outcome | Benign, malignant, indeterminate, still tracking |
| Trigger | Action |
|---|---|
| Follow-up overdue by 30 days | Alert to ordering provider via EMR message |
| Follow-up overdue by 60 days | Escalate to department quality lead |
| Follow-up overdue by 90 days | Direct patient contact per institutional policy |
| Patient declines follow-up | Document informed refusal; notify ordering provider |
| Finding upgraded on follow-up | Expedited referral; update tracking status |
| Patient transferred care | Forward tracking record to new provider |